Is 300204.SZ overvalued or undervalued?

300204.SZ currently has a P/E ratio of -111.31. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Staidson (Beijing) BioPharmaceuticals Co., Ltd. stock?

Staidson (Beijing) BioPharmaceuticals Co., Ltd. trades on SHZ. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 300204.SZ?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 300204.SZ protect my money against local inflation?

Many investors in Latin America buy international stocks like 300204.SZ to protect their purchasing power. Because 300204.SZ is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 300204.SZ shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 300204.SZ a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 300204.SZ diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks300204.SZ

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

¥20.66+¥0.40+1.97%

SHZ / CNY

Market cap

¥9.4B

P/E

-111.3

EPS (TTM)

¥-0.03

Dividend yield

—

Beta

0.44

1Y return

-38.69%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$92M2021

$80M2022

$51M2023

$44M2024

$31M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.19Low
Current ratio1.73
Cash ratio0.88
Net margin-47.9%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

300204.SZ-111.3
Healthcare sector median26.8
S&P 50022.0

Trades about 515% below its sector, cheaper than its peers on earnings.

Ratios

PEG-4.62
Price to book12.23
EPS (TTM)¥-0.03
Payout ratio-37%
FCF yield-1.52%

Range & risk

¥18.98¥42.65

Trading in the lower third of its 52-week band

Beta0.44

Profile

What Staidson (Beijing) BioPharmaceuticals Co., Ltd. actually does

Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.

CEO

Wang Chao

Employees

491

Headquarters

Beijing, BE

Founded

2011-04-15

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 300204.SZ and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

300204.SZ has a beta of 0.44, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.